Cartesian Therapeutics Inc Dossier - Source-backed chat

Cartesian Therapeutics Inc

RNACNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.74

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.22Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $218.4M

Enterprise Value $123.7M

Shares Outstanding 28.2M diluted

Next Earnings Date31 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cartesian Therapeutics is a late clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for autoimmune diseases. Its lead asset, Descartes-08, is an autologous anti-BCMA mRNA CAR-T therapy designed to be administered in an outpatient setting without the need for preconditioning chemotherapy. This represents a major paradigm shift compared to conventional DNA-based CAR-T therapies, which require lymphodepleting chemotherapy and carry significant safety risks. With an ongoing Phase 3 trial in myasthenia gravis (AURORA) and newly initiated trials in myositis (TRITON) and juvenile dermatomyositis (HELIOS), Cartesian is well-positioned to capture a substantial share of the underserved autoimmune cell therapy market. Backed by a strong cash runway extending into mid-2027 and non-dilutive financing, the company offers a highly asymmetric risk-reward profile ahead of its pivotal Phase 3 data readout in Q1 2027.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$16.00

Mean target$34.57

High · most bullish analyst$44.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$16.0020%

The Phase 3 AURORA trial fails to show a statistically significant improvement compared to placebo at Month 4, or unexpected serious adverse events emerge that compromise the outpatient administration profile. The development of Descartes-08 is delayed or halted, and the company's cash runway is depleted faster than expected, forcing highly dilutive equity raises or restructuring.

Base CaseCentral scenario

$34.5755%

Matches the consensus mean

The Phase 3 AURORA trial successfully meets its primary endpoint (≥3-point MG-ADL improvement at Month 4) in Q1 2027, confirming the deep and durable responses observed in Phase 2b. Descartes-08 maintains its favorable safety profile, supporting outpatient dosing. Cartesian prepares for a BLA filing in mid-2027. The TRITON and HELIOS trials progress steadily, validating the platform's applicability across multiple autoimmune indications. The stock trades in line with the consensus analyst price target.

Bull CaseUpside scenario

$44.0025%

Descartes-08 demonstrates superior efficacy and an pristine safety profile in the Phase 3 AURORA trial, meeting its primary endpoint with high statistical significance. Outpatient administration without preconditioning is validated, driving rapid clinical adoption. The Phase 2 TRITON trial in myositis yields highly positive interim results from the first 10 patients, allowing Cartesian to transition directly into a single pivotal trial. The company secures lucrative global partnerships, and the stock converges toward the high-end analyst price targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated mRNA CAR-T platform (RNA Armory®) enables transient, controllable expression, eliminating the need for toxic preconditioning chemotherapy and allowing safe outpatient administration.
Lead asset Descartes-08 is in a Phase 3 trial (AURORA) for generalized myasthenia gravis, a clinical program named among the trials shaping medicine in 2026.
Robust financial position with $120.4 million in cash as of March 31, 2026, supplemented by up to $150 million in non-dilutive financing from K2 HealthVentures, funding operations into mid-2027.
Rapidly expanding pipeline with the initiation of the Phase 2 TRITON trial in myositis and the Phase 1/2 HELIOS trial in juvenile dermatomyositis.

Key Investment Risks

Clinical development risk: Descartes-08 may fail to meet its primary efficacy endpoints in the Phase 3 AURORA trial or show insufficient durability of response.
Regulatory risk: The FDA may require additional clinical data or raise manufacturing hurdles before accepting a BLA filing.
Competition: The autoimmune cell therapy space is highly competitive, with multiple players developing DNA-based CAR-T, CAR-NK, and other modalities.
Single-asset concentration: The company's valuation is heavily dependent on the clinical and commercial success of Descartes-08.

Thesis Invalidation Triggers

Failure of the Phase 3 AURORA trial to meet its primary endpoint of a ≥3-point MG-ADL improvement at Month 4 compared to placebo.
Emergence of severe, systemic safety signals (e.g., cytokine release syndrome or neurotoxicity) requiring hospitalization or preconditioning chemotherapy.
Inability to initiate or enroll patients in the Phase 2 TRITON myositis trial on the projected timeline.
Severe cash burn acceleration that shortens the operational runway to well before the Q1 2027 topline data readout.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.